Jasper Therapeutics rises as company explores sale, strategic options

Jasper Therapeutics

01/06/2026 13:28

** Shares of biotech company Jasper Therapeutics JSPR.O rise 5% to 87 cents premarket 
** JSPR says it was exploring strategic alternatives, including a potential sale, as it looks to maximize shareholder value
** Jasper was developing experimental drug, briquilimab, for mast cell-driven diseases, including chronic spontaneous and inducible urticaria and asthma, in early-stage studies
** Co says its board would evaluate options such as asset sales or licensing, partnerships, a merger, or a sale of the company, as well as a possible wind-down
** Co adds it would review cost-cutting measures to preserve cash while maintaining regulatory compliance, but did not set a timeline for the process
** Up to last close, stock down 54.7% YTD

 (Reporting by Siddhi Mahatole)
 ((siddhi.mahatole@thomsonreuters.com))